Order the AmplideX PCR/CE CFTR Kit*

Solve Cystic Fibrosis Testing Coverage Challenges

Many commercially available CFTR panels were designed using variant information from disease databases that are heavily skewed toward individuals with European ancestry, making equitable coverage for ethnically diverse populations challenging. To address these coverage gaps, Asuragen, a Bio-Techne brand’s AmplideX PCR/CE CFTR Kit was designed with diversity in mind and based on recent, large-scale population studies that include data from a range of ethnic groups more representative of the U.S. population.

Although more than 2100 CFTR variants have been documented, these variants differ in levels of pathogenicity and prevalence between ethnicities.¹ ACOG guidelines state full gene sequencing is inappropriate for screening and should be reserved for specific clinical cases, so it is paramount to have a commercially available, targeted panel with a selection of variants that provides equitable coverage and is less likely to miss carriers in diverse populations.²

Figure 1.

Most CFTR panels have been designed from CFTR Databases that were historically³ skewed towards one ethnicity even though the U.S. population looks more like the Beauchamp et al. database.

Asuragen Addresses Critical Coverage Gaps in CFTR Panels

Table 2.

Designed to solve complex CFTR coverage challenges to provide the broadest coverage† of the U.S. population of any available targeted kit with an easy-to-use AmplideX workflow and a complementary assay portfolio.

Solve Cystic Fibrosis Testing Coverage Challenges

Many commercially available CFTR panels were designed using variant information from disease databases that are heavily skewed toward individuals with European ancestry, making equitable coverage for ethnically diverse populations challenging. To address these coverage gaps, Asuragen, a Bio-Techne brand’s AmplideX PCR/CE CFTR Kit was designed with diversity in mind and based on recent, large-scale population studies that include data from a range of ethnic groups more representative of the U.S. population.

Although more than 2100 CFTR variants have been documented, these variants differ in levels of pathogenicity and prevalence between ethnicities.¹ ACOG guidelines state full gene sequencing is inappropriate for screening and should be reserved for specific clinical cases, so it is paramount to have a commercially available, targeted panel with a selection of variants that provides equitable coverage and is less likely to miss carriers in diverse populations.²

Figure 1.

Most CFTR panels have been designed from this type of CFTR2 Database even though the U.S. population looks more like the Beauhchamp et al. database.

Asuragen Addresses Critical Coverage Gaps in CFTR Panels

Table 2.

Designed to solve complex CFTR coverage challenges to provide the broadest coverage† of the U.S. population of any available targeted kit with an easy-to-use AmplideX workflow and a complementary assay portfolio.